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Abstract
Skin necrosis is a rare but serious complication of subcutaneously administered low-molecular-
weight heparin. We report a case of a 53-year-old female patient with skin necrosis induced by
subcutaneous administration of nadroparine. The patient suffered from essential thrombocythae-
mia on a background of chronic myeloproliferative disease. She was admitted to our clinic with a
subacute ileus due to endometriosis of the rectosigmoid junction. She underwent a high anterior
resection and she received pre- and postoperative antithrombotic prophylaxis with subcutaneous
nadroparine on a daily basis. On the 6
th and 7
th postoperative days, two skin necroses occurred at
two injection sites.
Introduction
Skin necrosis following subcutaneously administered low-
molecular-weight heparin (LMWH) is a rare but serious
complication. It is believed that skin necrosis, amongst
other thrombotic complications observed, are the result of
LMWH-induced platelet aggregation followed by intravas-
cular thrombosis. According to current literature, 24 cases
of LMWH-induced necroses have been reported. Three of
those cases occurred following nadroparine injections. All
24 cases are reporting on patients with thrombocytopenia.
Our case is the only thrombocytotic patient amongst all
published cases. The aim of this paper is to report on a rare
case of skin necrosis following nadroparine injections on a
patient with thrombocytosis.
Case presentation
A 45-year-old Caucasian female patient, with a known
history of essential thrombocythaemia on a background of
chronic myeloproliferative disease, was admitted to our
clinic with a subacute ileus. Laboratory blood tests
revealed the following results: Glucose 88 mg/dl, urea
17 mg/dL, creatinine 0.6 mg/dL, SGOT 33 iu/L, SGPT
24 iu/L, gGT 99 iu/L, LDH 418 iu/L, CRP 0.1, total
bilirubin 0.7 µmol/L, direct bilirubin 0.35 µmol/L, anti-
HCV positive, WCC 9.83 x 10
9/L, Ht 32.2, PLT 768
(Normal value: >150–300 x 10
9/L).
All coagulation parameters, including protein S and C
activity, antithrombin III activity, activated partial
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centration and fibrinogen degradation products, were
within normal range. Computed tomography (CT) of the
abdomen (after gastrograffin intake) revealed spleen
distention and stenosis at the rectosigmoid junction. The
following day the patient was taken to the operation
theatre and the patient underwent a high anterior
resection, due to endometriosis of the rectosigmoid
junction. On postoperative blood test results, the platelet
count was constantly high, ranging between 800 & 900 x
10
9/L. During her stay in our clinic, the patient received
piperacillin-tazobactam 4.5gr intravenously (I.V.) for one
day, omeprazole 40mg I.V. for two days and 0.6 ml of
nadroparine subcutaneously to the abdominal wall, on a
daily basis. On the sixth postoperative day, the patient
complained of pain in the right lower abdomen, at the site
of the nadroparine injections and a purple discoloration
appeared on the right lower site of the abdominal wall.
Within 24 hours of the onset of pain, a necrotic eschar
surrounded by erythema had formed on the right lower
abdomen (Figure 1). The necrotic margins were well
demarcated. One day later a second lesion appeared onthe
left side (Figure 2). Subcutaneous injections of nadropar-
ine were stopped. The pain at the necrotic areas became
severe. The patient developed spiking pyrexia, reaching a
maximum of 38.7°C. The fever was thought to be a result
of the necroses. The lesions were treated conservatively
and they gradually settled. The skin returned to its normal
appearance 4–5 weeks later.
Discussion
Essential thrombocytosis is an acquired myeloproliferative
disorder, characterized by the overproduction of platelets
by megakaryocytes in the bone marrow in the absence of
an alternative cause. Arterial and venous thromboses
represent the main risks for patients suffering from
essential thrombocytosis [1,2].
Low molecular weight heparins are currently used as the
standard anti-thrombotic therapy. Skin necrosis caused by
LMWH is a rare complication. 24 cases have been reported
up to today, and only 3 of these cases occurred during
nadroparine administration [3]. All reported cases
occurred on patients with concomitant thrombocytopenia
(platelet count <300,000 cells/ml) rather than thrombo-
cytosis, as was the case in our patient. In our case, the
determination of Platelet Factor 4 (PF4)-induced anti-
bodies tested positive on Enzyme-Linked ImmunoSorbent
Assay (ELISA). Even though our patient had an increased
number of platelets, an absolute or even relative decrease
of the platelet count is often the only abnormality
observed during routine laboratory tests in patients with
LMWH-induced skin necroses.
Heparin-dependent IgG antibodies, which activate pla-
telets via their Fc receptors, are regularly found on
patients with LMWH-induced skin necroses, indepen-
dent of the type of LMWH used or of whether the
necroses occur locally at the injection sites or further
away [4,5]. These antibodies are specific for complexes
consisting of heparin and PF4, which are recognized by
the antibody, resulting in antibody-mediated vascular
injury [6,7]. It is believed that heparin causes platelet
aggregation in vessels surrounding the site of injection,
with subsequent thrombosis. The presence of fibrin
thrombi in the veins and capillaries of fresh histopatho-
logical specimens lends further strength to this proposi-
tion. Histological examination of LMWH-induced skin
necrosis specimens reveals microvascular thrombi in the
dermal vessels with minimal inflammation and without
signs of vasculitis [3].
Figure 1.
Necrotic eschar at nadroparine injection site.
Figure 2.
Second lesion one day later at the left side of the abdomen.
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the times between the 6
th and 12
th day after the first
injection [8]. It is possible that LMWH has a low
immunogenic profile and therefore requires repeated
exposure in order to lead to skin necrosis [3]. The diagnosis
of heparin-induced platelet aggregation should be strongly
suspected whenever necrosis occurs at an injection site.
Once skin necrosis is noticed or suspected, the initial
therapeutic action is to immediately stop the LMWH
therapy. The administrationof anyothertype of (fractioned
or unfractioned) LMWH isnot recommended, due to a well
known cross reaction of the heparin-dependent antibodies
amongst the above products. Should further anticoagula-
tion be necessary, one has the option of acetyl-salicylic acid
(ASA) or protamin [7,9–11]. Even though Coumarins may
be used, there is a published report on coumarin-induced
skin necrosis following HIT syndrome [12].
Conclusion
In conclusion, skin necrosis following subcutaneously
administered low-molecular-weight heparin (LMWH) is a
rare but serious complication. It represents a localized
manifestation of heparin-induced platelet aggregation and
thrombosis.
List of abbreviations
LMWH, Low molecular weight heparin; SGOT, Serum
Glutamic Oxaloacetic transaminase; SGPT, Serum Gluta-
mic Pyruvic Transaminase; gGT, Gamma-glutamyl Trans-
ferase; LDH, Lactate Dehydrogenase; CRP, C-Reactive
Protein; WCC, White Cell Count; HCV, Hepatitis C
Virus; Ht, Hematocrit; PLT, Platelet Count; PF4, Platelet
Factor 4; ASA, Acetylsalicylic Acid; HIT, Heparin-induced
thrombocytopenia; Fc, Fragment, crystallizable.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The author(s) declare that they have no competing
interests.
Authors’ contribution
MGP, SP and IK performed thepatient’s surgery.MGP, DK,
SP and IK assessed the patient on a daily basis and
observed the skin abnormalities. MGP and SP wrote the
manuscript and performed the data analysis. DK per-
formed the data collection, the image editing, the manu-
script drafting and the revision. IK analyzed and
interpreted the patient data and was a major contributor
in revising the manuscript and giving the final approval.
All authors read and approved the final manuscript.
References
1. Elliott MA, Tefferi A: Thrombosis and haemorrhage in
polycythaemia vera and essential thrombocythaemia. Br J
Haematol 2005, 128:275-290.
2. Michiels JJ, Berneman Z, Bockstaele DV, van der Planken M, De Raeve
H, Schroyens W: Clinical and laboratory features, pathology of
platelet-mediated thrombosis and bleeding complications
and the molecular etiology of essential thrombocythemia
and polycythemia vera: therapeutic implications. Semin Thromb
Hemost. 2006, 32:174-207.
3. Handschin AE, Trentz O, Kock HJ, Wanner GA: Low molecular
weight heparin-induced skin necrosis - a systematic review.
Langenbecks Archives of Surgery 2005, 390:249-254.
4. Tietge UJF, Schmidt HH-J, Jackel E, Trautwein C, Manns M.P: Low
molecular weight heparin-induced skin necrosis occurring
distant from injection sites and without thrombocytopenia.
Journal of Internal Medicine 1998, 243:313-315.
5. Santamaria A, Romani J, Souto JC, Lopez A, Mateo J, Fontcuberta J:
Skin necrosis at the injection site induced by low-molecular-
weight heparin: case report and review. Dermatology 1998,
196:264-265.
6. Eika C: Inhibition of Thrombin Induced Aggregation of
Human Platelets by Heparin. Scand J Haematol 1971, 8:216.
7. Eika C: On the Mechanism of Platelet Aggregation Induced by
Heparin, Protamine and Polybrene. Scand J Haematol 1972,
9:248.
8. Ojeda E, Perez MC, Mataix R, Arbelo R, Jimenez S, Campo C, Balda I:
Skin necrosis with a low molecular weight heparin. Br J
Haematol 1992, 82:620.
9. Landolfi R, Di Gennaro L, Novarese L, Patrono C: Aspirin for the
control of platelet activation and prevention of thrombosis in
essential thrombocythemia and polycythemia vera: current
insights and rationale for future studies. Semin Thromb Hemost
2006, 32:251-259.
10. Van Genderen PJJ, Mulder PGH, Weleboer M, Van de Moesdijk D,
Michiels JJ: Prevention and treatment of thrombotic complica-
tions in essential thrombocythaemia: efficacy and safety of
aspirin. Br J Haematol. 1997, 97:179-184.
11. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ: Aspirin in
essential thrombocythemia: status quo and quo vadis. Semin
Thromb Hemost 1997, 23:371-377.
12. Faraci PA, Deterling RA, Stein AM: Warfarin Induced Skin
Necrosis. Surg Gynecol Obstet 1978, 146:695.
Page 3 of 3
(page number not for citation purposes)
Cases Journal 2009, 2:6458 http://casesjournal.com/casesjournal/article/view/2/3/6458
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com